Details:
Data showed that targeting bile acid reuptake with linerixibat, an ileal bile acid transporter (IBAT inhibitor), could provide relief for patients with cholestatic pruritus in PBC.
Lead Product(s): Linerixibat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: GSK2330672
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2020